文献速递神经MR

非罗莫司醇增强MRI在检出颅内转移性疾病及转移灶大小方面不劣于钆增强MRI

Ferumoxytol-Enhanced MRI Is Not Inferior to Gadolinium-Enhanced MRI in Detecting Intracranial Metastatic Disease and Metastasis Size.
PubMed 文献 · AJR Am J Roentgenol · 2020-10-14

该个体内比较研究回顾性分析19例脑转移患者的非罗莫司醇增强与钆增强MRI,两名神经放射科医师独立测量强化转移灶数目和大小,结果显示两种对比剂在病灶数目和大小上无显著差异,非罗莫司醇增强MRI检出颅内转移性疾病不劣于钆增强MRI。

要点

  • 非罗莫司醇增强MRI检出颅内转移灶数目与钆增强MRI无显著差异。
  • 非罗莫司醇增强MRI显示转移灶各平面平均尺寸较钆增强MRI大约1.0–1.1 mm,差异无统计学意义。
  • 当钆增强MRI禁忌时,非罗莫司醇增强MRI可能改善脑转移患者的检查和监测。

核心结论

  • 非罗莫司醇增强MRI检出颅内转移性疾病不劣于钆增强MRI。
  • 若钆增强MRI存在禁忌,非罗莫司醇增强MRI可能改善脑转移患者的检查和监测。

研究设计与样本

  • 个体内比较研究,回顾性分析两项正在进行的非罗莫司醇增强和钆增强MRI方案研究中的患者影像。
  • 共纳入19例脑转移患者,原发肿瘤包括肺癌7例、乳腺癌3例、黑色素瘤3例、卵巢癌2例、结肠癌1例、肾细胞癌1例、类癌1例、子宫癌1例。
  • 两名神经放射科医师独立测量非罗莫司醇增强MRI和对照钆增强MRI上的强化转移灶。
  • 采用线性混合效应模型比较钆增强与菲罗莫司醇增强MRI之间体积立方根的差异,采用符号秩检验评估阅片者间的差异。

关键影像表现/征象

  • 阅片者1在非罗莫司醇增强MRI上识别77个肿块,在钆增强MRI上识别72个肿块。
  • 阅片者2在非罗莫司醇增强MRI上识别83个肿块,在钆增强MRI上识别78个肿块。
  • 阅片者1:非罗莫司醇增强MRI所示肿瘤各平面平均尺寸较钆增强MRI大1.1 mm(p = 0.1887)。
  • 阅片者2:非罗莫司醇增强MRI所示肿瘤各平面平均尺寸较钆增强MRI大1.0 mm(p = 0.2892)。
  • 两种对比剂之间及阅片者之间转移灶数目和肿瘤大小均无显著差异。

临床应用与阅片要点

  • 在钆增强MRI禁忌的脑转移患者中,可考虑使用非罗莫司醇增强MRI进行检出和监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The goal of this intraindividual comparison study was to investigate whether ferumoxytol-enhanced MRI is as effective as standard-of-care gadolinium-enhanced MRI in detecting intracranial metastatic disease. MATERIALS AND METHODS. We retrospectively reviewed all patients who underwent imaging as part of two ongoing ferumoxytol-enhanced and gadolinium-enhanced MRI protocol studies to compare the number and size of enhancing metastatic lesions. Two neuroradiologists independently measured enhancing metastases on ferumoxytol-enhanced MR images and on control gadolinium-enhanced MR images. The number and size of metastases were compared on an intraindividual basis. Primary diagnoses were recorded. A linear mixed-effects model was used to compare differences in cubic root of volume between gadolinium-enhanced and ferumoxytol-enhanced MRI. A signed rank test was used to evaluate differences between reviewers. RESULTS. MR images from 19 patients with brain metastases were analyzed (seven with lung cancer, three with breast cancer, three with melanoma, two with ovarian cancer, one with colon cancer, one with renal cell carcinoma, one with carcinoid tumor, and one with uterine cancer). Reviewer 1 identified 77 masses on ferumoxytol-enhanced MRI and 72 masses on gadolinium-enhanced MRI. Reviewer 2 identified 83 masses on ferumoxytol-enhanced MRI and 78 masses on gadolinium-enhanced MRI. For reviewer 1, ferumoxytol-enhanced MRI showed a mean tumor size measuring 1.1 mm larger in each plane compared with gadolinium-enhanced MRI (p = 0.1887). For reviewer 2, ferumoxytol-enhanced MRI showed a mean tumor size measuring 1.0 mm larger in each plane (p = 0.2892). No significant differences in number of metastases or tumor sizes were observed between contrast agents or reviewers. CONCLUSION. Intracranial metastatic disease detection with ferumoxytol-enhanced MRI was not inferior to detection with gadolinium-enhanced MRI. Ferumoxytol-enhanced MRI could improve workup and monitoring of patients with brain metastases if gadolinium-enhanced MRI is contraindicated.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Hamilton BE, Barajas R, Nesbit GM, et al. Ferumoxytol-Enhanced MRI Is Not Inferior to Gadolinium-Enhanced MRI in Detecting Intracranial Metastatic Disease and Metastasis Size. AJR Am J Roentgenol. 2020. PMID: 33052739. doi:10.2214/AJR.19.22187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。